Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| BIIB | Biogen, Inc. | 1.01% | 296.83 | 1.4% | $601.48m | |
| AMGN | Amgen, Inc. | 0.32% | 236.74 | 1.3% | $495.31m | |
| GILD | Gilead Sciences, Inc. | -2.75% | 65.77 | 1.0% | $370.34m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 1.15% | 376.42 | 2.6% | $305.23m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -0.71% | 218.98 | 1.9% | $275.99m | |
| ILMN | Illumina, Inc. | 0.85% | 324.72 | 3.5% | $241.12m | |
| CLVS | Clovis Oncology, Inc. | -4.24% | 12.86 | 14.7% | $219.13m | |
| SRPT | Sarepta Therapeutics, Inc. | 31.43% | 132.05 | 14.6% | $207.70m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -1.82% | 110.42 | 2.0% | $199.61m | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | -1.28% | 66.46 | 11.4% | $199.52m | |
| A | Agilent Technologies, Inc. | -1.30% | 83.71 | 1.6% | $164.84m | |
| EXAS | EXACT Sciences Corp. | 2.08% | 87.20 | 24.0% | $164.17m | |
| BLUE | bluebird bio, Inc. | 6.78% | 89.75 | 14.2% | $152.73m | |
| GBT | Global Blood Therapeutics, Inc. | -0.01% | 76.88 | 6.0% | $140.08m | |
| BOLD | Audentes Therapeutics, Inc. | 0.05% | 59.40 | 1.4% | $136.27m |
Company Profile
Epizyme, Inc. is a clinical-stage biopharmaceutical company, which engage in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. It also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.